South-East Asia (WHO region) vs Switzerland: Hypertension: effective treatment coverage (controlled hypertension)
South-East Asia (WHO region)
13.3%
in 2019
Switzerland
37.9%
in 2019
South-East Asia (WHO region) rank
13th
Switzerland rank
12th
Hypertension: effective treatment coverage (controlled hypertension) over time
- South-East Asia (WHO region)
- Switzerland
How they compare
Switzerland currently reports 37.9% against 13.3% in South-East Asia (WHO region), a difference of 24.6%.
That makes Switzerland's figure about 2.8 times South-East Asia (WHO region)'s.
Across all 30 years both countries report, Switzerland has been ahead every year.
South-East Asia (WHO region) ranks 13th and Switzerland ranks 12th of 17 groups.
Switzerland has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | South-East Asia (WHO region) | Switzerland | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 2.6% | 9.8% | 7.2% | Switzerland |
| 2000s | 5.7% | 20.6% | 15.0% | Switzerland |
| 2010s | 10.7% | 33.6% | 22.9% | Switzerland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hypertension: effective treatment coverage (controlled hypertension), South-East Asia (WHO region) or Switzerland?
- Switzerland, at 37.9% against 13.3% in South-East Asia (WHO region) as of 2019.
- What is the difference in hypertension: effective treatment coverage (controlled hypertension) between South-East Asia (WHO region) and Switzerland?
- 24.6%, with Switzerland ahead.
- How many years of comparable data are there for South-East Asia (WHO region) and Switzerland?
- 30 years are reported by both, from 1990 to 2019.
- How do South-East Asia (WHO region) and Switzerland rank globally for hypertension: effective treatment coverage (controlled hypertension)?
- South-East Asia (WHO region) ranks 13th and Switzerland ranks 12th of 17 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hypertension: effective treatment coverage (controlled hypertension) among adults aged 30-79 with hypertension, crude (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.